Citi lifts GSK target price but keeps neutral stance after rally

Citi raised its GSK price target to £22.50 while maintaining a neutral rating after the stock’s strong rally, noting FY2025 EPS came in ~2% ahead of consensus and 2026 constant‑currency guidance broadly matched expectations. The broker trimmed 2026–27 EPS forecasts by 1–2% due to FX headwinds and vaccine assumptions but left long‑term earnings largely unchanged, and highlighted management’s R&D focus under new CEO Luke Miels, the RAPT Therapeutics deal and the company’s ambition to underpin a £40bn 2031 revenue target with flat margins through dolutegravir loss of exclusivity. Citi said further pipeline progress (multiple phase III starts and potential pivotal trials in 2026–27) will be needed to fully deliver sales and margin goals; shares were quoted flat at 2,205p.

Analysis

Market structure: The immediate winners are GSK (LSE:GSK / NYSE:GSK) equity holders and small-cap partners like RAPT (RAPT) if milestone-linked upside materialises; peers with heavy reliance on legacy HIV revenue may lose relative investor interest. Citi’s modestly higher £22.50 TP versus a 2,205p price implies only ~2% upside, signifying a re-rating that’s largely priced in — expect limited further P/E expansion absent binary pipeline wins. FX headwinds cited by Citi mean EPS sensitivity to GBP moves; a sustained GBP decline of >3% vs USD could trim consensus EPS by ~1–3% into 2026/27, while credit spreads should be resilient absent earnings shocks.

Risk assessment: Tail risks are classic binary pharma events: a pivotal Phase III failure or regulatory rejection in 2026–27 could erase >20% of market value; conversely one positive pivotal could add 15–30%. Immediate (days) risk is sentiment reversal; short-term (weeks–months) hinge on clinical starts and 2026 guidance cadence; long-term (years) depends on replacing dolutegravir revenue towards the £40bn 2031 target. Hidden dependencies include RAPT deal milestones, milestone timing, and management’s ability to keep margins flat through LOE.

Trade implications: For investors seeking asymmetric upside, establish a measured 2–3% long position in GSK within two weeks, target 12-month price 2,450–2,550p (10–16% upside), and protect with a 6–12 month put at ~1,900p (stop ~14% downside). Use a paired trade (long GSK 2% vs short PFE 2%) to isolate R&D re-rating, horizon 6–12 months. If using options, buy a 12-month call spread 2,200p/2,750p sized to 0.5–1% notional to cap cost while retaining upside to pipeline catalysts.

Contrarian angles: Consensus underweights execution risk — Citi’s neutral stance despite a higher TP signals limited upside and that the market has already rewarded management’s rhetoric; this suggests chasing the move is risky unless new trial data appears. The reaction may be overdone on sentiment: if GSK >2,350p (+7%) without concrete Phase III readouts, consider taking profits or initiating short-dated volatility sells. Historical parallels show R&D-driven CEO pivots often require 12–24 months of positive readouts to sustain re-ratings; absence of such readouts risks mean reversion.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (LSE:GSK) within the next 2 weeks; target 12-month exit at 2,450–2,550p (10–16% upside). Hedge with a 6–12 month protective put around 1,900p (stop-loss ~14% below entry).
• Implement a pair trade: long GSK 2% vs short Pfizer (PFE) 2% to isolate R&D re-rating over a 6–12 month horizon; rebalance if GSK or PFE moves >8% intraperiod.
• Deploy an options-defined upside trade: buy a 12-month call spread 2,200p/2,750p (size 0.5–1% notional) to capture upside to pipeline catalysts while limiting premium outlay.
• If GSK rallies above 2,350p without new Phase III starts/readouts, reduce new allocations and consider shorting strength (6–12 month horizon); set alerts for GBP moves >±3% vs USD and for any Phase III readout dates in 2026–27 to reassess positions.